Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5272472
Max Phase: Preclinical
Molecular Formula: C37H65N17O10S4
Molecular Weight: 1036.30
Associated Items:
ID: ALA5272472
Max Phase: Preclinical
Molecular Formula: C37H65N17O10S4
Molecular Weight: 1036.30
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
Standard InChI: InChI=1S/C37H65N17O10S4/c1-4-16(2)26(35(64)53-24-15-66-65-12-21(27(40)56)50-33(24)62)54-28(57)17(3)47-30(59)19(7-5-9-45-36(41)42)48-31(60)20(8-6-10-46-37(43)44)49-32(61)23-14-68-67-13-22(34(63)52-23)51-29(58)18(38)11-25(39)55/h16-24,26H,4-15,38H2,1-3H3,(H2,39,55)(H2,40,56)(H,47,59)(H,48,60)(H,49,61)(H,50,62)(H,51,58)(H,52,63)(H,53,64)(H,54,57)(H4,41,42,45)(H4,43,44,46)/t16-,17-,18-,19-,20-,21-,22-,23-,24-,26-/m0/s1
Standard InChI Key: CKCZUPCAYUIJPK-GJFKNRNDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1036.30 | Molecular Weight (Monoisotopic): 1035.3983 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Brust A, Croker DE, Colless B, Ragnarsson L, Andersson Å, Jain K, Garcia-Caraballo S, Castro J, Brierley SM, Alewood PF, Lewis RJ.. (2016) Conopeptide-Derived κ-Opioid Agonists (Conorphins): Potent, Selective, and Metabolic Stable Dynorphin A Mimetics with Antinociceptive Properties., 59 (6): [PMID:26859603] [10.1021/acs.jmedchem.5b00911] |
Source(1):